SEC Form 4 · accession 0001387131-15-001922
TherapeuticsMD, Inc. · TXMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mitchell Krassan
Officer — EVP, Chief Strategy Officer
Period of report
Jun 8, 2015
Accepted (ET)
Jun 10, 2015 · 6:22 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000025743
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 8, 2015 | M | 30,000 | $0.2037 | A | 30,000 | D | |
| Common StockF2 | Jun 8, 2015 | S | 30,000 | $8.18 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy) | $0.2037 | Jun 8, 2015 | M | 30,000 | D | Oct 4, 2011 | May 1, 2020 | Common Stock | 30,000 | 683,955 | D |
Explanation of responses
- F1The shares were sold pursuant to a 10b5-1 Sales Plan dated September 8, 2014.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.08 to $8.42, inclusive. The reporting person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.